TTR and familial amyloid neuropathy: That is, effective systemic therapies are treatments targeting the liver, their inhibitory effects on variant TTR production in the pigment epithelium [9,10] is low, and amyloid oculopathy characterized by pupillary shape abnormalities, amyloid deposition in the lens, vitreous amyloidosis, and secondary glaucoma characterized by high intraocular pressure [27,28] cannot be suppressed in patients with ATTRv amyloidosis.